News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,890 Results
Type
Article (39930)
Company Profile (248)
Press Release (663712)
Multimedia
Podcasts (56)
Webinars (14)
Section
Business (204251)
Career Advice (2011)
Deals (35444)
Drug Delivery (95)
Drug Development (81114)
Employer Resources (172)
FDA (16231)
Job Trends (14882)
News (345420)
Policy (32587)
Tag
Academia (2556)
Accelerated approval (7)
Adcomms (22)
Allergies (94)
Alliances (49560)
ALS (104)
Alzheimer's disease (1422)
Antibody-drug conjugate (ADC) (150)
Approvals (16226)
Artificial intelligence (300)
Autoimmune disease (26)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (113)
Biotechnology (175)
Bladder cancer (89)
Brain cancer (32)
Breast cancer (355)
Cancer (2766)
Cardiovascular disease (204)
Career advice (1681)
Career pathing (30)
CAR-T (177)
CDC (29)
Cell therapy (482)
Cervical cancer (22)
Clinical research (66684)
Collaboration (977)
Company closure (3)
Compensation (639)
Complete response letters (19)
COVID-19 (2615)
CRISPR (53)
C-suite (298)
Cystic fibrosis (109)
Data (2853)
Decentralized trials (2)
Denatured (20)
Depression (52)
Diabetes (339)
Diagnostics (6416)
Digital health (23)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (133)
Drug pricing (118)
Drug shortages (27)
Duchenne muscular dystrophy (120)
Earnings (87381)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113632)
Executive appointments (838)
FDA (17800)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (900)
Gene editing (124)
Generative AI (21)
Gene therapy (361)
GLP-1 (767)
Government (4483)
Grass and pollen (4)
Guidances (180)
Healthcare (18837)
Huntington's disease (29)
IgA nephropathy (37)
Immunology and inflammation (137)
Immuno-oncology (7)
Indications (39)
Infectious disease (2773)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (58)
Intellectual property (114)
Interviews (312)
IPO (16578)
IRA (44)
Job creations (3635)
Job search strategy (1424)
Kidney cancer (13)
Labor market (51)
Layoffs (486)
Leadership (18)
Legal (7923)
Liver cancer (78)
Lung cancer (389)
Lymphoma (199)
Machine learning (9)
Management (58)
Manufacturing (363)
MASH (85)
Medical device (13438)
Medtech (13443)
Mergers & acquisitions (19548)
Metabolic disorders (822)
Multiple sclerosis (96)
NASH (16)
Neurodegenerative disease (109)
Neuropsychiatric disorders (30)
Neuroscience (2069)
NextGen: Class of 2025 (6516)
Non-profit (4487)
Now hiring (47)
Obesity (415)
Opinion (216)
Ovarian cancer (97)
Pain (100)
Pancreatic cancer (115)
Parkinson's disease (184)
Partnered (22)
Patents (286)
Patient recruitment (147)
Peanut (50)
People (57619)
Pharmaceutical (63)
Pharmacy benefit managers (20)
Phase I (20781)
Phase II (29371)
Phase III (21861)
Pipeline (1565)
Policy (190)
Postmarket research (2563)
Preclinical (8847)
Press Release (64)
Prostate cancer (134)
Psychedelics (33)
Radiopharmaceuticals (252)
Rare diseases (440)
Real estate (5914)
Recruiting (66)
Regulatory (22524)
Reports (50)
Research institute (2324)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (45)
Schizophrenia (80)
Series A (149)
Series B (100)
Service/supplier (11)
Sickle cell disease (57)
Special edition (18)
Spinal muscular atrophy (147)
Sponsored (31)
Startups (3584)
State (2)
Stomach cancer (13)
Supply chain (73)
Tariffs (55)
The Weekly (34)
Vaccines (755)
Venture capital (50)
Weight loss (252)
Women's health (43)
Worklife (16)
Date
Today (133)
Last 7 days (538)
Last 30 days (2547)
Last 365 days (31411)
2025 (15788)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (719)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38147)
Australia (6227)
California (7246)
Canada (2274)
China (648)
Colorado (308)
Connecticut (312)
Delaware (187)
Europe (81978)
Florida (1084)
Georgia (243)
Hawaii (1)
Idaho (59)
Illinois (623)
India (26)
Indiana (357)
Iowa (16)
Japan (217)
Kansas (108)
Kentucky (28)
Louisiana (14)
Maine (64)
Maryland (1003)
Massachusetts (5379)
Michigan (244)
Minnesota (441)
Mississippi (3)
Missouri (87)
Montana (28)
Nebraska (25)
Nevada (78)
New Hampshire (66)
New Jersey (2018)
New Mexico (28)
New York (2044)
North Carolina (1056)
North Dakota (8)
Northern California (3190)
Ohio (229)
Oklahoma (15)
Oregon (34)
Pennsylvania (1576)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (33)
South Dakota (1)
Southern California (2692)
Tennessee (123)
Texas (1082)
United States (26887)
Utah (214)
Virginia (180)
Washington D.C. (72)
Washington State (615)
West Virginia (4)
Wisconsin (63)
703,890 Results for "epivax inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
May 28, 2025
·
3 min read
Press Releases
The Role of Treg Epitopes (Tregitopes) in Antibody Maturation Uncovered in New EpiVax Study: Implications for Therapeutic Antibodies
April 22, 2025
·
2 min read
Press Releases
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
February 28, 2025
·
3 min read
Press Releases
EpiVax Drives Immunogenicity Innovation in 2024: Year in Review
December 9, 2024
·
2 min read
Drug Development
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening
EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for preclinical immunogenicity risk assessment of Eisai’s robust biologics pipeline.
December 20, 2023
·
2 min read
Genetown
Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations.
August 11, 2023
·
2 min read
Press Releases
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
October 25, 2024
·
3 min read
Genetown
Providence-based “Biotech start up” EpiVax Celebrates 25th Anniversary
EpiVax, Inc. is celebrating its 25th birthday by renewing the company’s commitment to improving human health everywhere while highlighting the development of groundbreaking tools by the company.
May 17, 2023
·
3 min read
Business
EpiVax and Zoetis to Collaborate on Swine T cell Epitope Prediction Tool: CircoMatch™
EpiVax, Inc. (“EpiVax”) and Zoetis, are pleased to announce an exclusive collaboration to develop CircoMatch™, a unique bioinformatics tool that predicts the coverage of Porcine Circovirus Type 2 (PCV2) vaccines against field isolates of PCV2.
January 10, 2023
·
2 min read
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
EpiVax, Inc. (“EpiVax”) is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2.
October 31, 2022
·
2 min read
1 of 70,389
Next
